|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
chemotherapy
|
|
gptkbp:approvalYear
|
2018
2023-10-27
|
|
gptkbp:approvedBy
|
gptkb:nasopharyngeal_carcinoma
gptkb:China
gptkb:United_States
melanoma
|
|
gptkbp:associatedWith
|
gptkb:pembrolizumab
gptkb:cemiplimab
gptkb:nivolumab
|
|
gptkbp:ATCCode
|
L01FF11
|
|
gptkbp:brand
|
gptkb:Loqtorzi
Tuoyi
|
|
gptkbp:CASNumber
|
1925026-50-6
|
|
gptkbp:clinicalTrialPhase
|
gptkb:NCT02915432
gptkb:NCT03013101
gptkb:NCT03581786
Phase III
|
|
gptkbp:developedBy
|
gptkb:Coherus_BioSciences
gptkb:Shanghai_Junshi_Biosciences
|
|
gptkbp:EMAStatus
|
not approved (as of 2024)
|
|
gptkbp:halfLife
|
~17 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Toripalimab
|
|
gptkbp:indication
|
gptkb:advanced_melanoma
other solid tumors (investigational)
unresectable or metastatic nasopharyngeal carcinoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
IgG4 monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
immunotherapy
|
|
gptkbp:molecularWeight
|
~146 kDa
|
|
gptkbp:monitors
|
oncologist
|
|
gptkbp:origin
|
humanized antibody
|
|
gptkbp:prescribes
|
adults
pediatric patients (in some indications)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
pruritus
hepatitis
rash
pneumonitis
immune-related adverse events
endocrinopathies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:PD-1
|
|
gptkbp:UNII
|
6K7C6QFW2K
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|